Furthermore, better screening modalities for SARS-CoV-2 and Cpn and/or biomarkers consistent with these infections within pathologic tissue samples may be necessary to unequivocally demonstrate their involvement in AD pathogenesis. This evidence concerns the gene CPN1 and Alzheimer disease.